BioArctic AB (publ) (BIOA-B.ST)
SEK 163.0
(-3.89%)
SEK 163.0
(-3.89%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 275.38 Million SEK | 6735.23% |
| 2022 | 4.21 Million SEK | 103.18% |
| 2021 | -126.42 Million SEK | -70.17% |
| 2020 | -74.58 Million SEK | -160.28% |
| 2019 | 123.36 Million SEK | -74.98% |
| 2018 | 487.88 Million SEK | 2171.89% |
| 2017 | 26.01 Million SEK | -71.33% |
| 2016 | 64.23 Million SEK | 1093.21% |
| 2015 | 6.36 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -67.97 Million SEK | -18.47% |
| 2024 Q1 | -57.37 Million SEK | 23.3% |
| 2023 Q1 | 310.46 Million SEK | 674.1% |
| 2023 Q4 | -74.8 Million SEK | -151.41% |
| 2023 Q2 | -96.3 Million SEK | -131.02% |
| 2023 Q3 | 145.52 Million SEK | 251.11% |
| 2023 FY | - SEK | 6735.23% |
| 2022 Q3 | 140.6 Million SEK | 434.86% |
| 2022 FY | - SEK | 103.18% |
| 2022 Q4 | -54.07 Million SEK | -138.46% |
| 2022 Q2 | -41.98 Million SEK | -3.65% |
| 2022 Q1 | -40.5 Million SEK | -11.87% |
| 2021 Q2 | -30.55 Million SEK | -19.34% |
| 2021 Q1 | -25.6 Million SEK | 8.24% |
| 2021 Q4 | -36.21 Million SEK | -6.33% |
| 2021 Q3 | -34.05 Million SEK | -11.47% |
| 2021 FY | - SEK | -70.17% |
| 2020 Q3 | -17.62 Million SEK | 50.18% |
| 2020 Q4 | -27.89 Million SEK | -58.29% |
| 2020 FY | - SEK | -160.28% |
| 2020 Q1 | 7.41 Million SEK | 138.58% |
| 2020 Q2 | -35.37 Million SEK | -577.2% |
| 2019 FY | - SEK | -74.98% |
| 2019 Q4 | -19.21 Million SEK | -145.5% |
| 2019 Q3 | -7.82 Million SEK | -106.0% |
| 2019 Q2 | 130.36 Million SEK | 550.67% |
| 2019 Q1 | 20.03 Million SEK | -95.35% |
| 2018 FY | - SEK | 2171.89% |
| 2018 Q2 | 7.18 Million SEK | -64.39% |
| 2018 Q4 | 430.87 Million SEK | 1159.79% |
| 2018 Q1 | 20.17 Million SEK | 29.03% |
| 2018 Q3 | 34.2 Million SEK | 376.09% |
| 2017 Q3 | 619 Thousand SEK | -82.14% |
| 2017 FY | - SEK | -71.33% |
| 2017 Q4 | 15.63 Million SEK | 2426.17% |
| 2017 Q2 | 3.46 Million SEK | 135.87% |
| 2017 Q1 | 1.46 Million SEK | -98.48% |
| 2016 Q1 | -5.87 Million SEK | 0.0% |
| 2016 FY | - SEK | 1093.21% |
| 2016 Q4 | 96.39 Million SEK | 1063.5% |
| 2016 Q3 | -10 Million SEK | 8.03% |
| 2016 Q2 | -10.87 Million SEK | -85.08% |
| 2015 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Simris Alg AB (publ) | -22.36 Million SEK | 1331.44% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 186.745% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 197.644% |
| Xintela AB (publ) | -53.47 Million SEK | 615.021% |
| Active Biotech AB (publ) | -43.88 Million SEK | 727.491% |
| Amniotics AB (publ) | -27.14 Million SEK | 1114.578% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | 2037.026% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 174.874% |
| Camurus AB (publ) | 562.54 Million SEK | 51.046% |
| Cantargia AB (publ) | -284.31 Million SEK | 196.86% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 1506.543% |
| CombiGene AB (publ) | -35.33 Million SEK | 879.337% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 295.517% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 1711.91% |
| Genovis AB (publ.) | 64.57 Million SEK | -326.481% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 339.661% |
| Mendus AB (publ) | -97.84 Million SEK | 381.449% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 843.807% |
| Intervacc AB (publ) | -68.98 Million SEK | 499.227% |
| Kancera AB (publ) | -61.88 Million SEK | 544.969% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 1128.216% |
| LIDDS AB (publ) | -39.67 Million SEK | 794.195% |
| Lipum AB (publ) | -37.11 Million SEK | 841.903% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | 2375.173% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | -776.917% |
| NextCell Pharma AB | -40.98 Million SEK | 771.919% |
| OncoZenge AB (publ) | 7.26 Million SEK | -3690.077% |
| Saniona AB (publ) | -69.69 Million SEK | 495.132% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 262.169% |
| Ziccum AB (publ) | -20.34 Million SEK | 1453.785% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | -13769250.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 215.897% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | 13339.76% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 2150.383% |
| Corline Biomedical AB | -1.69 Million SEK | 16385.452% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 258.886% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 602.476% |
| Aptahem AB (publ) | -10 Million SEK | 2851.331% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | -2284.509% |
| Fluicell AB (publ) | -25.91 Million SEK | 1162.696% |
| Biovica International AB (publ) | -119.5 Million SEK | 330.438% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 752.205% |
| AcouSort AB (publ) | -16.7 Million SEK | 1748.728% |
| Abliva AB (publ) | -93.6 Million SEK | 394.192% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 186.301% |
| 2cureX AB (publ) | -35.13 Million SEK | 883.774% |
| I-Tech AB | 30.34 Million SEK | -807.52% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 138.54% |
| Cyxone AB (publ) | -20.41 Million SEK | 1449.01% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 368.793% |
| Biosergen AB | 228 Thousand SEK | -120683.772% |
| Nanologica AB (publ) | -62.11 Million SEK | 543.322% |
| SynAct Pharma AB | -222.7 Million SEK | 223.658% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 727.863% |
| BioInvent International AB (publ) | -312.7 Million SEK | 188.066% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | -88903.048% |
| Alzinova AB (publ) | 41.99 Thousand SEK | -655598.945% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 218.895% |
| Pila Pharma AB (publ) | -8.81 Million SEK | 3224.967% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 353.677% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | 2501.142% |